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Abstract
Currently, opioid-based drugs are the most effective pain relievers that are widely used in the
treatment of pain. However, the analgesic efficacy of opioids is significantly limited by the
development of tolerance after repeated opioid administration. Glutamate receptors have been
reported to critically participate in the development and maintenance of opioid tolerance, but the
underlying mechanisms remain unclear. Using whole-cell voltage-clamp recordings in brainstem
slices, the present study investigated chronic morphine-induced adaptations in glutamatergic
synaptic transmission in neurons of the nucleus raphe magnus (NRM), a key supraspinal relay for
pain modulation and opioid analgesia. Chronic morphine significantly increased glutamate synaptic
transmission exclusively in one class of NRM cells that contains µ-opioid receptors in a morphine-
tolerant state. The adenylyl cyclase activator forskolin and the cAMP analog 8-bromo-cAMP
mimicked the chronic morphine effect in control neurons and their potency in enhancing the
glutamate synaptic current was significantly increased in neurons from morphine-tolerant rats.
MDL12330a, an adenylyl cyclase inhibitor, and H89, a protein kinase A (PKA) inhibitor, reversed
the increase in glutamate synaptic transmission induced by chronic morphine. In addition, PMA, a
phorbol ester activator of protein kinase C (PKC), also showed an increased potency in enhancing
the glutamate synaptic current in these morphine-tolerant cells. The PKC inhibitor GF109203X
attenuated the chronic morphine effect. Taken together, these results suggest that chronic
morphine increases presynaptic glutamate release in µ receptor-containing NRM neurons in a
morphine-tolerant state, and that the increased glutamate synaptic transmission appears to involve
an upregulation of both the cAMP/PKA pathway and the PKC pathway. This glutamate-mediated
activation of these NRM neurons that are thought to facilitate spinal pain transmission may
contribute to the reduced opioid analgesia during opioid tolerance.
Background
Opioid analgesics, such as morphine, currently are the
most effective and frequently used pain reliever for mod-
erate to severe pain. However, long-term administration
of opioids can alter the central pain-related systems and
results in opioid tolerance (decreased analgesic effect of
opioids) and opioid dependence (a behavioral state
requiring continued opioids to avoid a series of aversive
withdrawal syndromes). Opioid tolerance and depend-
ence significantly hamper the effective treatment of
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chronic pain with opioid analgesics [1]. Numerous ago-
nists and antagonists of various receptors and inhibitors
of second messenger pathways have been reported to
block or reduce morphine tolerance and/or dependence
[2]. It has been well established that glutamate receptors
are critical in the development and maintenance of opioid
tolerance [3-6]. However, the underlying mechanisms by
which glutamate receptors mediate opioid tolerance and
dependence remain unclear. An upregulation of the
cAMP/PKA signaling pathway has been characterized as a
typical molecular adaptation in several brain regions fol-
lowing chronic morphine treatment [1], but the detailed
role of the cAMP pathway in analgesic tolerance to
chronic opioids has yet to be demonstrated.
Nucleus raphe magnus (NRM), a key medullary relay for
descending pain modulation, is critically involved in opi-
oid-induced analgesia [7]. According to their electrophys-
iological characters and opioid responses, NRM neurons
in an in vitro preparation have been divided into two gen-
eral types, primary cells that lack the µ-opioid receptor and
secondary cells that contain the µ receptor [8]. Based on the
observation that acute opioids inhibit GABA synaptic
transmission in primary cells, we have proposed that opi-
oids produce analgesia in the NRM by disinhibiting or
activating those primary cells that send descending projec-
tions to the spinal dorsal horn and inhibit spinal pain
transmission [8,9]. Several lines of evidence suggests that
some NRM cells that are directly inhibited by opioids or
contain µ receptors have a facilitating action on spinal
pain transmission through their descending projections
[7,10,11]. Thus, both activation of pain-inhibiting pri-
mary cells and inhibition of pain-facilitating secondary
cells in the NRM may be involved in acute opioid-induced
analgesia. The synaptic connections between primary cells
and secondary cells and the neurotransmitter they release
are currently unknown. Accumulating evidence has
clearly demonstrated that the µ receptor-containing cells
in the NRM are activated in many chronic pain conditions
with pain sensitization [11-13], but the activation mecha-
nisms remain unclear. The present study was aimed to
investigate chronic morphine-induced adaptation of
glutamate synaptic transmission in NRM neurons from
morphine-tolerant rats and the intracellular signaling
pathways involved in the synaptic adaptation.
Results
Chronic morphine selectively increases presynaptic 
glutamate release
Glutamate-mediated excitatory postsynaptic currents
(EPSCs) were recorded under whole-cell voltage-clamp in
NRM slices in vitro. The EPSCs were compared between
NRM slices from saline-treated control rats and those
from morphine-treated tolerant rats. Both groups of slices
(control and tolerant) were maintained in 5 µM mor-
phine throughout recording experiment in vitro to prevent
morphine withdrawal (Ingram et al., 1998). A separate
group of control slices kept in a morphine-free solution
(normal group) was used as controls for the acute mor-
phine added. We used the paired-pulse ratio (PPR) to
assess chronic morphine-induced changes in glutamate
synaptic transmission in the two types of NRM neurons,
primary cells and secondary cells. In the µ receptor-con-
taining secondary cells in control slices, the average PPR
was 1.76 ± 0.05 (n = 16), indicating a common synaptic
facilitation (PPR>1) by the two stimuli. However, in sec-
ondary cells from morphine-tolerant rats, the PPR was sig-
nificantly smaller than that in controls (1.43 ± 0.07, n =
41, P < 0.01, Fig. 1A,C), indicating an increased probabil-
ity of presynaptic glutamate release in these secondary
cells in a morphine-tolerant state. The PPR in secondary
cells in the normal group without 5 µM morphine was
1.89 ± 0.13 (n = 33), which was not statistically different
from that in control cells kept in 5 µM morphine (p >
0.05), excluding possible effect of the acute morphine on
the PPR. In contrast to secondary cells, there was no signif-
icant difference between the EPSC PPRs in µ receptor-lack-
ing primary cells from control and from morphine-
tolerant rats (control, 1.43 ± 0.11, n = 10; tolerant, 1.44 ±
0.08, n = 17; P > 0.05, Fig 1B,C). These data indicate that
chronic morphine increases glutamate synaptic transmis-
sion selectively in the µ receptor-containing secondary
cells in a morphine-tolerant state.
EPSC-enhancing effect of activators of cAMP pathway is 
increased
In control secondary cells, bath application of the adeny-
lyl cyclase (AC) activator forskolin (10 µM) significantly
increased the amplitude of evoked EPSCs (eEPSCs) by
53.9 ± 4.1% (control, 95.1 ± 7.3 pA, forskolin, 144.1 ±
14.2 pA, n = 12, P < 0.01). Forskolin produced a compa-
rable EPSC increase in secondary cells in normal slices
without 5 µM morphine (57.4 ± 11.4%, n = 6, p < 0.01, p
> 0.05 when compared to its effect in control slices with 5
µM morphine). However, in tolerant secondary cells, the
EPSC-enhancing effect of forskolin was significantly
increased to 95.3 ± 5.3% (p < 0.01, compared to its effect
in control group) (control, 88.9 ± 7.8 pA, forskolin, 174.3
± 13.9 pA, n = 7, P < 0.01, Fig. 2A,B). Similar to the effect
of chronic morphine, forskolin (10 µM) also significantly
decreased the PPR of glutamate EPSCs in secondary cells
from both saline-treated and morphine-tolerant rats
(saline: control, 1.73 ± 0.21, forskolin, 1.03 ± 0.14, n = 5,
P < 0.01; tolerant: control, 1.43 ± 0.14, forskolin, 0.90 ±
0.03, n = 5, P < 0.01, Fig 2C). Due to a significant decrease
in the basal PPR, direct comparison in percentage term of
the forskolin effects between the two groups was not fea-
sible. In primary cells, by contrast, although forskolin
increased the eEPSC amplitude in both control and toler-
ant groups, the magnitude of its effects in the two groupsMolecular Pain 2005, 1:7 http://www.molecularpain.com/content/1/1/7
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was not changed (control, 72.8 ± 17.6%, n = 7, tolerant,
67.0 ± 14.9%, n = 5, P > 0.05).
To further confirm the forskolin effect on presynaptic
glutamate release, we examined forskolin action on mini-
ature EPSCs (mEPSCs) in NRM neurons. In control sec-
ondary cells, forskolin (10 µM) increased the frequency,
but not the amplitude, of glutamate mEPSCs (frequency:
control, 5.70 ± 1.03 Hz, forskolin, 8.46 ± 1.07 Hz, n = 5,
P < 0.05; amplitude: control, 20.8 ± 2.0 pA, forskolin,
20.6 ± 2.4 pA, n = 5, P > 0.05). This forskolin effect was
also observed in secondary cells from tolerant rats (fre-
quency: control, 7.64 ± 0.96 Hz, forskolin, 15.18 ± 0.98
Hz, n = 5, P < 0.01; amplitude: control, 21.3 ± 2.4 pA, for-
skolin, 20.5 ± 2.23 pA, n = 5, P > 0.05). By comparison,
the forskolin-induced increase in the mEPSC frequency
Chronic morphine decreases the paired-pulse ratio (PPR) of  glutamate EPSCs in µ-opioid receptor-containing cells  (termed secondary cells) in the NRM from morphine-toler- ant rats Figure 1
Chronic morphine decreases the paired-pulse ratio (PPR) of 
glutamate EPSCs in µ-opioid receptor-containing cells 
(termed secondary cells) in the NRM from morphine-toler-
ant rats. A, Representative EPSC pairs in secondary cells 
from a saline-treated rat, a morphine-treated tolerant rat and 
the same two EPSC pairs normalized to the first EPSC. B, 
Representative EPSC pairs in the other type of NRM cells 
(termed primary cells) lacking the µ receptor from two simi-
lar groups of rats. C, Group data of the PPR in the two cell 
types from saline control and morphine-tolerant rats. Stimu-
lus artifacts are blanketed. Numbers in columns indicate cell 
numbers. ** p < 0.01.
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EPSC-enhancing effect of Forskolin is increased in secondary  cells from morphine-tolerant rats Figure 2
EPSC-enhancing effect of Forskolin is increased in secondary 
cells from morphine-tolerant rats. A, Glutamate EPSCs 
before (control) and during bath application of forskolin (10 
µM) in cells from saline control and tolerant rats. B, Time 
course for the forskolin enhancement of EPSC amplitudes in 
saline control (n = 12) and tolerant cells (n = 7). The hori-
zontal bar indicates application time for forskolin. C, Nor-
malized EPSC pairs in the absence (control) and presence of 
forskolin in saline control and tolerant cells. Note forskolin-
induced decrease in the PPR of both groups. Forsk, forskolin. 
* p < 0.05, ** p < 0.01.
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was significantly greater in tolerant secondary cells
(control, 54.2 ± 9.8%, tolerant, 104.3 ± 11.5%, n = 5, P <
0.05, Fig 3 & Fig. 4D). The forskolin-induced increase in
mEPSC frequency in tolerant primary cells was not altered
(control, 62.6 ± 17.4%, n = 4, tolerant, 72.2 ± 36.4%, n =
5, P > 0.05).
The cAMP analog 8-bromo-cAMP (8-br-cAMP) produced
similar effects to those of forskolin. Bath application of 8-
br-cAMP (1 mM) increased the eEPSC amplitude in sec-
ondary cells from both saline control and morphine-tol-
erant rats (saline: control, 110.9 ± 14.8 pA, 8-br-cAMP,
166.6 ± 9.2 pA, n = 4, P < 0.01; tolerant: control, 130.1 ±
1.4 pA, 8-br-cAMP, 260.2 ± 28.5 pA, n = 7, P < 0.001). This
cAMP effect was significantly enhanced by chronic mor-
phine treatment (saline, 52.1 ± 9.4%, tolerant, 103.6 ±
10.1%, p < 0.05). 8-br-cAMP also decreased the PPR in
secondary cells from both saline control and tolerant rats
(saline: control, 1.70 ± 0.08, 8-br-cAMP, 1.10 ± 0.07, n =
4, P < 0.01; tolerant: control, 1.49 ± 0.17, 8-br-cAMP, 1.14
± 0.10, n = 5, P < 0.05, Fig 4A,B).
Bath application of 8-br-cAMP (1 mM) also significantly
increased the frequency of mEPSC in secondary cells from
both saline control and tolerant rats (saline: control, 4.72
± 0.47 Hz, 8-br-cAMP, 6.85 ± 0.70 Hz, n = 8, p < 0.01; tol-
erant: control, 6.62 ± 0.88 Hz, 8-br-cAMP, 12.46 ± 1.25
Hz, n = 7, p < 0.01, Fig. 4C). However, similar to the for-
skolin effect, this effect of 8-br-cAMP was also signifi-
cantly enhanced in the slices from morphine-tolerant rats
(saline, 46.9 ± 7.9%, n = 8, tolerant, 97.5 ± 21.2%, n = 7,
p < 0.05, Fig. 4D). 8-br-cAMP did not change the ampli-
tudes of mEPSCs in either group (saline: control, 15.9 ±
0.6 pA, 8-br-cAMP, 15.9 ± 1.3 pA, n = 8, P > 0.05; tolerant:
control, 18.8 ± 1.2 pA, 8-br-cAMP, 18.9 ± 1.6 pA, n = 7, P
> 0.05).
The enhanced forskolin and 8-br-cAMP effects on eEPSC
amplitude and mEPSC frequency in morphine-tolerant
rats indicate a sensitized or upregulated AC system in a
morphine-tolerant state.
Chronic morphine-induced EPSC increase involves cAMP 
pathway
To determine the involvement of the AC pathway in the
chronic morphine-induced increase of glutamate release
in NRM secondary cells, NRM slices were treated with
MDL12330a, a selective AC inhibitor. While pre-incuba-
tion with MDL12330a (100 µM) did not change the EPSC
PPR in secondary cells from control rats (control, 1.71 ±
0.06, MDL, 1.76 ± 0.03, n = 5, p > 0.05), it largely reversed
the chronic morphine-induced PPR decrease in secondary
cells from morphine-tolerant rats (tolerant, 1.43 ± 0.07,
+MDL, 1.74 ± 0.07, n = 16, P < 0.01, Fig. 5A,B,C). Bath
application of MDL12330a (100 µM) also significantly
decreased the frequency of mEPSCs in tolerant secondary
cells (tolerant, 10.17 ± 0.89 Hz, +MDL, 5.86 ± 0.66 Hz, n
= 5, P < 0.01, Fig. 5D,E,F) whereas it did not alter the
mEPSC amplitude (tolerant, 16.9 ± 1.1 pA, +MDL, 18.1 ±
1.2 pA, n = 5, P > 0.05). MDL had no effect on either the
frequency or the amplitude of mEPSCs in secondary cells
from saline control rats (frequency: control, 4.39 ± 0.45
Hz, +MDL, 4.71 ± 0.50 Hz, n = 5, P > 0.05; amplitude:
control, 16.9 ± 2.0 pA, +MDL, 17.5 ± 1.5 pA, n = 5, P >
0.05, Fig. 5F). Next, we used a PKA inhibitor to determine
whether PKA was involved in the enhanced glutamate
transmission in secondary cells induced by chronic mor-
phine. Pre-incubation with H89 (10 µM) largely inhibited
the chronic morphine-induced decrease of the EPSC PPR
in secondary cells from morphine-tolerant rats (tolerant,
1.43 ± 0.07, +H89, 1.71 ± 0.06, n = 13, P < 0.01, Fig.
Forskolin enhancement of miniature EPSC (mEPSC) fre- quency is greater in secondary cells from morphine-tolerant  rats Figure 3
Forskolin enhancement of miniature EPSC (mEPSC) fre-
quency is greater in secondary cells from morphine-tolerant 
rats. A,B,C, Representative current traces with miniature 
synaptic events (A) and plots of cumulative distribution of 
mEPSC frequency (B) and amplitude (C) before and during 
application of forskolin (10 µM) in the same saline control 
cell. D,E,F, Current traces (D) and plots of mEPSC distribu-
tion data (E,F) from a tolerant cell.
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6A,B). H89 was without effect on the EPSC PPR in second-
ary cells from control rats (tolerant, 1.76 ± 0.06, +H89,
1.90 ± 0.08, n = 6, P > 0.05, Fig. 6B). Similarly, bath appli-
cation of H89 (10 µM) significantly decreased the fre-
quencies, but not the amplitude, of mEPSCs in tolerant
secondary cells (frequency: tolerant, 8.55 ± 2.42 Hz,
+H89, 4.66 ± 2.11 Hz, n = 5, P < 0.05; amplitude: tolerant,
15.1 ± 0.9 pA, +H89, 14.3 ± 0.7 pA, n = 5, P > 0.05, Fig
6C,D). In control secondary cells, H89 did not change
either the frequency or the amplitude of mEPSCs (fre-
quency: control, 3.96 ± 0.44 Hz, +H89, 3.43 ± 0.62 Hz, n
= 5, P > 0.05; amplitude: control, 20.5 ± 3.8 pA, +H89,
20.2 ± 3.0 pA, n = 5, P > 0.05, Fig. 6D).
These data obtained with both MDL12330a and H89 sug-
gest that the cAMP/PKA pathway is critically involved in
the chronic morphine-induced enhancement of gluta-
mate synaptic transmission in NRM secondary cells.
Chronic morphine-induced EPSC increase involves PKC 
pathway
Finally, we examined whether the PKC pathway was also
involved in the chronic morphine effect on glutamate
EPSCs. Phorbol 12-myristate 13-acetate (PMA, 1 µM), a
phorbol ester activator of PKC, increased the amplitude of
eEPSCs in NRM secondary cells from both saline control
and morphine-tolerant rats (saline: control, 109.9 ± 15.8
pA, PMA, 180.4 ± 22.2 pA, n = 7, P < 0.001; tolerant: con-
trol, 134.8 ± 12.9 pA, PMA, 284.7 ± 25.8 pA, n = 7, P <
0.01, Fig. 7A). However, when the PMA effects were com-
pared between the two groups, the EPSC-enhancing effect
of PMA was significantly larger in cells from tolerant rats
than that in control cells (control, 67.7 ± 6.9%, n = 7, tol-
erant, 126.6 ± 16.4%, n = 7, p < 0.01, Fig. 7B), indicating
a likely upregulated PKC pathway. GF109203X (2 µM), a
selective PKC inhibitor, had no significant effect on the
EPSC PPR in control secondary cells (control, 1.76 ± 0.14,
EPSC-enhancing effect of 8-bromo-cAMP is increased in secondary cells from morphine-tolerant rats Figure 4
EPSC-enhancing effect of 8-bromo-cAMP is increased in secondary cells from morphine-tolerant rats. A, Normalized EPSC 
pairs in control and in 8-broma-cAMP (8-br-cAMP, 1 mM) in a saline control cell and a tolerant cell. B, Group data of 8-br-
cAMP-induced decrease in the PPR in saline control (n = 4) and tolerant cells (n = 5). C, Distribution data of mEPSC frequency 
before and during application of 8-br-cAMP in a saline control (left) and a tolerant cell (right). D, Percent increase by 8-br-
cAMP and forskolin in mEPSC frequency in saline control and tolerant cells.
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GF109203X, 1.76 ± 0.05, n = 6, P > 0.05), but it reversed
the chronic morphine-induced decrease of the EPSC PPR
in secondary cells from morphine-tolerant rats (tolerant,
1.43 ± 0.07, +GF109203X, 1.79 ± 0.10, n = 8, P < 0.05, Fig.
7C,D,E).
Discussion
The present study has illustrated that chronic morphine
increases presynaptic release of glutamate in the µ recep-
tor-containing secondary cells in a morphine-tolerant
state. It also provides evidence that both cAMP/PKA and
PKC signaling pathways are critically involved in this
chronic morphine-induced synaptic adaptation during
morphine tolerance.
Upregulation of the cAMP pathway and glutamate release
In the present study, the effect of chronic morphine on
glutamate synaptic transmission was primarily assessed
by using the paradigm of EPSC PPR in NRM neurons kept
in a tolerant state from morphine-tolerant rats [14]. The
PPR has been widely used to determine the involvement
of a presynaptic site in the mechanism of neurotransmit-
ter release [15-21]. A change in the PPR is inversely related
to the probability of transmitter release and thus, a
manipulation that increases the probability of transmitter
release results in a reduction in the PPR and vise versa.
Since the PPR in a cell under a certain condition is rela-
tively stable, the advantage of using the PPR is to avoid
MDL12330a reverses the chronic morphine effect on gluta- mate EPSCs in tolerant secondary cells Figure 5
MDL12330a reverses the chronic morphine effect on gluta-
mate EPSCs in tolerant secondary cells. A, Representative 
EPSC pairs in tolerant cells without (tolerant) and after treat-
ment with the adenylyl cyclase (AC) inhibitor MDL12330a 
(MDL, 100 µM). B, Normalized EPSC pairs from A. C, 
Group data of the MDL effect on the PPR in cells from mor-
phine-tolerant (n = 16) and saline control rats (n = 5). D,E, 
Representative current traces (D) and a plot of mEPSC fre-
quency distribution (E) in a tolerant cell before and during 
application of MDL (100 µM). F, Group data of the MDL 
effect on mEPSC frequency in tolerant and saline control 
cells (n = 5 in each group).
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H89 reverses the chronic morphine effect on glutamate  EPSCs in tolerant secondary cells Figure 6
H89 reverses the chronic morphine effect on glutamate 
EPSCs in tolerant secondary cells. A, Normalized EPSC pairs 
in tolerant cells without and after treatment with H89 (10 
µM), a protein kinase A inhibitor. B, Group data of the H89 
effect on PPR in tolerant (n = 13) and saline control cells (n = 
6). C, A plot of mEPSC frequency distribution in tolerant 
cells with or without H89 treatment. D, Group data of the 
H89 effect on mEPSC frequency in tolerant and saline con-
trol cells (n = 5 in each group).
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large variance usually present in eEPSC amplitudes and
mEPSC frequencies among individual cells, making it
possible to compare EPSCs in two separate groups of
slices, such as those from saline-treated control rats and
those from morphine-tolerant rats. Our current results
obtained with the PPR analysis suggest that glutamate
synaptic transmission is enhanced through a presynaptic
mechanism in NRM secondary cells from morphine-toler-
ant rats. This conclusion is further supported by the effects
of activators and inhibitors of the cAMP/PKA or PKC path-
way, which mimicked and reversed the effect of chronic
morphine, respectively. It is interesting to note that the
chronic morphine-induced EPSC enhancement occurred
exclusively in µ receptor-containing secondary cells. This
may implicate a functional activation of these µ receptor-
expressing NRM cells by glutamate inputs during mor-
phine tolerance (see below). The source of these gluta-
mate inputs is currently unclear.
Presynaptic glutamate release is modulated by many com-
plex and interacting proteins and processes, including
components of the cAMP/PKA pathway, in presynaptic
terminals [22,23]. It has been demonstrated that in vitro
application of activators of the cAMP/PKA pathway
enhances presynaptic release of glutamate in many types
of central neurons [23-27]. In vivo administration of
chronic morphine induces adaptive hyperactivation of the
cAMP/PKA signaling pathway in several brain regions
[1,27,28]. The hyperactivated cAMP/PKA pathway
induced by chronic morphine may induce a series of
Chronic morphine-induced EPSC augmentation involves the protein kinase C pathway Figure 7
Chronic morphine-induced EPSC augmentation involves the protein kinase C pathway. A, Representative EPSCs in the absence 
and presence of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA, 1 µM) in a saline control cell and 
a tolerant cell. B, PMA effect on the peak amplitude of eEPSCs in saline control and tolerance cells. C,D, Representative EPSC 
pairs (C) and the same pairs after normalization (D) in tolerant cells with or without treatment with the PKC inhibitor 
GF109203X. E, Group data of the GF109203X effect on PPR in tolerant (n = 8) and saline control cells (n = 6).
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cellular adaptations, including enhanced transmitter
release. However, cAMP-dependent synaptic adaptation
induced by in vivo administration of chronic morphine
has been reported only in GABAergic synapses in central
neurons during morphine withdrawal [21,28,29]. The
current study provides direct evidence that chronic mor-
phine enhances glutamate synaptic transmission also in a
cAMP-dependent way in NRM neurons from morphine-
tolerant rats.
Several observations in the current study support a critical
role of an upregulated cAMP/PKA pathway in the
enhanced glutamate neurotransmission in secondary cells
from morphine-tolerant rats. First, the AC activator and
cAMP analog mimic the effect of chronic morphine on
EPSC PPR. Second, the potency of cAMP activators in
enhancing eEPSC amplitude and mEPSC frequency is sig-
nificantly augmented in neurons from morphine-tolerant
rats. Such an augmented effect has been interpreted as the
result of a sensitized or upregulated cAMP pathway
[21,27,29]. Finally, inhibitors of both AC and PKA reverse
the chronic morphine-induced EPSC enhancement. This
effect of AC/PKA inhibitors observed in tolerant cells, but
not in control cells, indicates an elevated basal activity of
the cAMP/PKA pathway induced by chronic morphine.
Such an upregulation of basal and stimulated PKA activity
has been shown in other brain areas [1,30].
Upregulation of the PKC pathway and glutamate release
It has been shown that activation of PKC either by the
intracellular messenger diacylglycerol or by phorbol esters
produces an enhancement of neurotransmitter release
including glutamate release in central neurons [23,31,32].
Activated PKC may phosporylate a number of proteins in
nerve terminal and increase neurotransmitter release by
calcium influx through voltage-gated calcium channels or
by direct effects on exocytosis or on vesicle-recycling path-
ways [33]. Chronic morphine increases PKC activity in the
rat brain and spinal cord [34,35]. The increased PKC activ-
ity, which may be mediated through opioid activation of
the phospholipase C pathway coupled to opioid recep-
tors, can phosphorylate AC and increase its adaptive
responses to chronic opioids [27,30]. In the present study,
the PKC activator, similar to activators of the cAMP/PKA
pathway, exhibited an augmented potency in enhancing
glutamate EPSCs in NRM neurons from morphine-toler-
ant rats, and the PKC inhibitor reversed the effect of
chronic morphine. Although non-specific effects of these
PKA and PKC inhibitors cannot be completely ruled out,
these data indicate a likely upregulated PKC and PKA
activity, which is at least partially responsible for the
enhanced glutamate synaptic transmission in NRM sec-
ondary cells from morphine-tolerant rats.
Functional implications in morphine tolerance
Extensive evidence has shown that some NRM cells inhib-
ited by µ opioids have a facilitating action on spinal pain
transmission through their descending projections [7,10].
Recent pain research shows that those brainstem cells
expressing µ-opioid receptors are commonly activated in
various chronic pain conditions, including chronic opi-
oid-induced abnormal pain, and contribute to the sensi-
tized pain or hyperalgesia observed during these
conditions [11-13,36]. It remains unclear what mediates
the activation of these µ receptor-containing cells in those
pain conditions. Data from the current study indicate that
excessive activity of glutamate synaptic inputs after
chronic exposure to opioids may contribute to the activa-
tion of these cells during morphine tolerance. An overall
effect of this enhanced glutamate synaptic activity in driv-
ing these cells needs to be evaluated by taking into
account other synaptic inputs such as GABA synaptic
transmission.
It has been proposed that the chronic opioid-induced acti-
vation of those presumably pain-facilitating cells and con-
sequently, abnormal pain, constitute part of the
mechanisms underlying opioid tolerance characterized by
a reduced analgesic effect of opioids [36]. For example,
microinjection of lidocaine into the NRM area to inacti-
vate cell activity reverses the tactile allodynia and thermal
hyperalgesia induced by prolonged exposure to mor-
phine, and attenuates morphine tolerance [37,38]. A crit-
ical role of glutamate receptors in the development of
opioid tolerance and dependence has been established [3-
6]. The present study illustrates an example of the mecha-
nisms by which glutamate receptors and synapses partici-
pate in the development of opioid tolerance. An
important role of PKC in opioid tolerance has also been
demonstrated in previous studies. For instance, PKC inhi-
bition reduces opioid tolerance [34,35,39,40], and PKCγ
mutant mice display alleviated morphine tolerance [41].
In summary, the current study shows that chronic mor-
phine enhances glutamate synaptic transmission in µ
receptor-containing NRM neurons. This synaptic
adaptation appears to be mediated by an upregulated
cAMP/PKA and PKC pathway in morphine-tolerant rats.
These results may provide key information for pain thera-
pies aiming at inhibiting those brainstem neurons and
their descending pain facilitation, which is responsible for
the pain sensitization in several chronic pain conditions.
Methods
All procedures involving the use of animals conformed to
the guidelines set by the University of Texas-MD Anderson
Cancer Center Animal Care and Use Committee. Chronic
morphine treatment Male, Wistar neonatal rats were
injected (i.p.) twice daily with morphine solutions for 6Molecular Pain 2005, 1:7 http://www.molecularpain.com/content/1/1/7
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days. The dose of the morphine was 10 mg/kg on the first
day, and increased by 5 mg/kg each day to reach a maxi-
mum dose of 30 mg/kg on day 5. On day 7, the rats were
euthanized for brain slice preparation. Saline was injected
at the same volume and schedule in a separate group of
rats for controls. Morphine tolerance in these neonatal
rats has been described previously [42].
Whole-cell voltage-clamp recording The methods for NRM
brain slice preparations, visualized whole-cell recordings,
cell classification and analysis of glutamate EPSCs have
been published previously [15]. The brain of a rat (10–14
days old) was cut in a vibratome in cold (4°C) physiolog-
ical saline to obtain brainstem slices (220–250 µm thick)
containing the NRM. A single slice was submerged in a
shallow recording chamber and perfused with preheated
(35°C) physiological saline (in mM: NaCl, 126; KCl, 2.5;
NaH2PO4, 1.2; MgCl2, 1.2; CaCl2, 2.4; glucose, 11;
NaHCO3, 25, saturated with 95% O2 and 5% CO2, pH
7.2–7.4). Slices were maintained at around 35°C
throughout the recording experiment. Neonatal rats were
used for better visualization of neurons in brain slices
with an infrared Nomarski microscope. It has been dem-
onstrated that the physiological and pharmacological
properties of neurons from these young rats are indistin-
guishable from those of adult rats[9,15]. Visualized
whole-cell voltage-clamp recordings were made from
identified neurons held at -60 mV with a glass pipette
(resistance 3–5 MΩ ) filled with a solution containing
(mM): potassium gluconate, 126; NaCl, 10; MgCl2, 1;
EGTA, 11; Hepes, 10; ATP, 2; GTP, 0.25; pH adjusted to
7.3 with KOH; osmolarity 280–290 mosmol/L. An Axo-
Patch 1-D amplifier and AxoGraph software 4.7 (Axon
Instruments, Inc.) were used for data acquisition and on-
line/off-line data analyses. A seal resistance of 2 GΩ  or
above and an access resistance of 15 MΩ  or less were con-
sidered acceptable. Series resistance was optimally com-
pensated. The access resistance was monitored
throughout the experiment. Electrical stimuli of constant
current (0.25 ms, 0.2–0.4 mA) were used to evoke EPSCs
with bipolar stimulating electrodes placed lateral (200–
400 µm) to the recording pipette within the NRM. The dif-
ference in glutamate synaptic transmission between con-
trol and morphine-tolerant slices was assessed by the
paradigm of paired-pulse ratio (PPR). A pair of EPSCs was
evoked by two stimuli with an interval of 40 ms. The PPR
was determined by dividing the second EPSC amplitude
by the first one. Miniature EPSCs were obtained in 60-sec
epochs in the presence of tetrodotoxin (1 µM). The Axo-
Graph software was used to detect and measure the ampli-
tude and intervals of the synaptic events, and to analyze
their distribution data. All NRM cells recorded were clas-
sified into either a µ-containing secondary cell or a µ-lack-
ing primary cell according to the criteria described in our
previous study [8]. NRM slices from both morphine- and
saline-treated rats were kept in 5 µM morphine through-
out the recording experiment to maintain the slices in a
morphine-tolerant state and prevent withdrawal [14].
Another group of slices from saline-treated rats kept in a
morphine-free solution was used as controls for the acute
morphine. Statistic analysis of mEPSCs were performed
with the Mann-Whitney U test or the Kolmogorov-Smir-
nov test using the Statview software. Other numeral data
were statistically analyzed with Students' t tests and pre-
sented as mean ± S.E.M. Some slices were incubated in
MDL12330a (100 µM), or H89 (10 µM) or GF109203X (2
µM) for at least 1 hour. Drugs were generally applied
through the bath solution unless otherwise specified.
Morphine sulfate was kindly supplied by the National
Institute on Drug Abuse. All other drugs were purchased
either from Sigma-Aldrich Co. or from Tocris Cookson
Inc. (Ellisville, MO).
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